RecruitingType 1 DiabetesNew Onset
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
Eligible age
9–20 yrs
Accepts
All genders
Locations
10 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.
Sponsor: City of Hope Medical Center
Where it's recruiting
California
San Francisco
Colorado
Aurora
Connecticut
New Haven
Florida
Gainesville · Miami
Indiana
Indianapolis
Minnesota
Minneapolis
New York
Buffalo
Pennsylvania
Pittsburgh
Texas
Houston
Washington
Seattle
Source: ClinicalTrials.gov · NCT07061574 · last updated 2026-06-02